share_log

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

武田的遺傳性血管水腫治療可防止12歲以下兒童發作
Benzinga Real-time News ·  2022/07/01 10:30
  • Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
  • The data demonstrated positive results of Takhzyro (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.
  • HAE attacks, which can involve serious and severely debilitating swelling in the abdomen, face, feet, genitals, hands, and throat, may occur very early in childhood. 
  • Takhzyro reduced the rate of HAE attacks in children by a mean of 94.8% compared to baseline, from 1.84 attacks per month to 0.08 attacks during treatment.
  • Most patients (76.2%) were attack-free during the 52-week treatment period, with an average of 99.5% attack-free days.
  • No deaths or serious treatment-emergent adverse events (TEAEs) were reported during the study, and no patients withdrew from the study due to TEAEs.
  • Price Action: TAK shares are down 0.64% at $13.95 during the market session on the last check Friday.
  • 武田藥品工業株式會社(紐約證券交易所市場代碼：Tak) 在2022年歐洲過敏和臨牀免疫學混合大會上公佈的第三階段春季研究的最新數據。
  • 數據顯示，Takhzyro(Lanadelumab)在預防遺傳性血管性水腫(HAE)發作方面取得了積極的結果，患者2至
  • HAE發作，包括腹部、面部、腳、生殖器、手和喉嚨的嚴重和嚴重虛弱的腫脹，可能發生在很小的兒童時期。
  • 與基線相比，Takhzyro將兒童HAE發作的發生率平均降低了94.8%，從每月1.84次發作減少到治療期間的0.08次發作。
  • 大多數患者(76.2%)在52周的治療期間沒有發作，平均99.5%的無發作天數。
  • 在研究期間，沒有死亡或嚴重的緊急治療不良事件(TEAE)的報告，也沒有患者因TEAE而退出研究。
  • 價格行動：在週五尾盤交易時段，德意志銀行股價下跌0.64%，至13.95美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論